US Patent No: 7,135,181

Number of patents in Portfolio can not be more than 2000

Method for down-regulation of amyloid

ALSO PUBLISHED AS: 20020187157

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
H. LUNDBECK A/SVALBY-COPENHAGEN181

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jensen, Martin Roland Holte, DK 14 66
Nielsen, Klaus Gregorius Søborg, DK 23 145
Rasmussen, Peter Birk Copenhagen, DK 30 125

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
5,192,688 Histological analysis method 10 1991
2004/0062,802 Maximizing effectiveness of substances used to improve health and well being 36 2003
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (1)
4,596,792 Safe vaccine for hepatitis containing polymerized serum albumin 50 1984
 
BAVARIAN NORDIC, INC. (1)
2004/0141,958 Novel methods for therapeutic vaccination 22 2003
 
MILKHAUS LABORATORY, INC. (1)
* 5,851,996 Materials and methods for treatment of plaquing diseases 88 1998
 
JANSSEN ALZHEIMER IMMUNOTHERAPY (3)
* 6,787,523 Prevention and treatment of amyloidogenic disease 63 1998
6,787,144 Prevention and treatment of amyloidogenic disease 52 2000
* 6,787,637 N-Terminal amyloid-.beta. antibodies 63 2000
 
Musashi Engineering Kabushiki Kaisha (1)
4,578,770 Method of discriminating sheet 39 1983
 
INTELLECT NEUROSCIENCES INC. (1)
* 2004/0091,945 Peptides and methods of screening immunogenic peptide vaccines against Alzheimer's Disease 8 2003
 
The Scripps Research Institute (2)
4,599,230 Synthetic hepatitis B virus vaccine including both T cell and B cell determinants 99 1984
4,599,231 Synthetic hepatitis B virus vaccine including both T cell and B cell determinants 89 1984
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
4,601,903 Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease 64 1985
 
TRUSTEES OF BOSTON UNIVERSITY (1)
5,200,339 Proteases causing abnormal degradation of amyloid .beta.-protein precursor 41 1991
 
SCHERING-PLOUGH ANIMAL HEALTH CORPORATION (1)
4,608,251 LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues 69 1984
 
ALCON RESEARCH, LTD. (1)
5,874,469 Fluoroalkyl hydrocarbons for administering water insoluble or unstable drugs 4 1996
 
H. LUNDBECK A/S (2)
* 2003/0086,938 Novel methods for down-regulation of amyloid 23 2002
2003/0157,117 Novel method for down-regulation of amyloid 17 2002
 
SCIOS NOVA INC. (1)
5,223,482 Recombinant Alzheimer's protease inhibitory amyloid protein and method of use 31 1989
 
GLAXOSMITHKLINE BIOLOGICALS S.A. (1)
* 6,544,518 Vaccines 45 2000
 
NEW YORK UNIVERSITY (1)
* 6,713,450 Synthetic immunogenic but non-amyloidogenic peptides homologous to amyloid .beta. for induction of an immune response to amyloid .beta. and amyloid deposits 41 2001
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
CROSSBETA BIOSCIENCES B.V. (3)
8,114,832 Method for detecting and/or removing a protein comprising a cross-beta structure from a pharmaceutical composition 0 2005
8,067,187 Cross-β structure binding compounds 0 2006
8,158,585 Cross-β structure comprising amyloid-binding proteins and methods for detection of the cross-β structure, for modulating cross-β structures fiber formation and modulating cross-β structure-mediated toxicity 0 2007
 
INTEZYNE TECHNOLOGIES, INC. (1)
7,618,944 Encapsulated amyloid-beta peptides 11 2008
 
ABBVIE DEUTSCHLAND GMBH & CO KG (1)
8,895,004 Method for the treatment of amyloidoses 0 2008
 
UNIVERSITY OF SOUTH FLORIDA (1)
8,188,046 Amyloid beta peptides and methods of use 0 2007
 
H. LUNDBECK A/S (1)
8,871,212 Amyloid-beta polypeptide vaccine 0 2008
 
ABBVIE INC. (4)
8,691,224 Anti-Aβ globulomer 5F7 antibodies 0 2006
8,497,072 Amyloid-beta globulomer antibodies 0 2006
8,455,626 Aβ conformer selective anti-aβ globulomer monoclonal antibodies 0 2007
8,877,190 Aβ conformer selective anti-Aβ globulomer monoclonal antibodies 0 2011
 
NEW YORK UNIVERSITY (2)
* 8,685,718 Mucosal immunization to prevent prion infection 0 2004
* 2007/0059,807 Mucosal immunization to prevent prion infection 1 2004
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 14, 2018
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00